Research ExplorerPublicationsMolecular targeting in combination with platinum-based chemo...

Molecular targeting in combination with platinum-based chemoradiation in head and neck cancer treatment

Standard

Molecular targeting in combination with platinum-based chemoradiation in head and neck cancer treatment. / Möckelmann, Nikolaus; Kriegs, Malte; Lörincz, Balazs B; Busch, Chia-Jung; Knecht, Rainald.

In: HEAD NECK-J SCI SPEC, Vol. 38, No. Suppl 1, 04.2016, p. E2173-81.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Möckelmann, N, Kriegs, M, Lörincz, BB, Busch, C-J & Knecht, R 2016, 'Molecular targeting in combination with platinum-based chemoradiation in head and neck cancer treatment', HEAD NECK-J SCI SPEC, vol. 38, no. Suppl 1, pp. E2173-81. https://doi.org/10.1002/hed.24031

APA

Möckelmann, N., Kriegs, M., Lörincz, B. B., Busch, C-J., & Knecht, R. (2016). Molecular targeting in combination with platinum-based chemoradiation in head and neck cancer treatment. HEAD NECK-J SCI SPEC, 38(Suppl 1), E2173-81. https://doi.org/10.1002/hed.24031

Vancouver

Möckelmann N, Kriegs M, Lörincz BB, Busch C-J, Knecht R. Molecular targeting in combination with platinum-based chemoradiation in head and neck cancer treatment. HEAD NECK-J SCI SPEC. 2016 Apr;38(Suppl 1):E2173-81. https://doi.org/10.1002/hed.24031

Bibtex

@article{c30b66b47c9c4c0b83e93ab068fc6463,
title = "Molecular targeting in combination with platinum-based chemoradiation in head and neck cancer treatment",
abstract = "BACKGROUND: Significant evidence exists supporting the use of platinum-based chemoradiation (CRT) as a primary curative approach in locoregionally advanced head and neck cancer (LA-HNSCC). Despite these aggressive protocols, 70% of patients die within five years due to locoregional recurrence or distant metastasis. To increase the response and survival of HNSCC patients, CRT has been combined with molecular agents targeting distinct kinases.METHODS: This study was performed using a systematic literature review.RESULTS: The effect of targeted therapy on patient survival in the context of CRT remains controversial, with toxicities tending to be more severe but still acceptable.CONCLUSIONS: Supplementing CRT with target therapeutics might only improve survival in some LA-HNSCC patients. Therefore, future studies must address the underlying biological mechanisms which can have an impact on treatment response. Such knowledge is essential in order to facilitate the effective and personalized treatment of LA-HNSCC patients by combining CRT and targeted therapy. This article is protected by copyright. All rights reserved.",
author = "Nikolaus M{\"o}ckelmann and Malte Kriegs and L{\"o}rincz, {Balazs B} and Chia-Jung Busch and Rainald Knecht",
note = "{\textcopyright} 2015 Wiley Periodicals, Inc.",
year = "2016",
month = apr,
doi = "10.1002/hed.24031",
language = "English",
volume = "38",
pages = "E2173--81",
journal = "HEAD NECK-J SCI SPEC",
issn = "1043-3074",
publisher = "John Wiley and Sons Inc.",
number = "Suppl 1",

}

RIS

TY - JOUR

T1 - Molecular targeting in combination with platinum-based chemoradiation in head and neck cancer treatment

AU - Möckelmann, Nikolaus

AU - Kriegs, Malte

AU - Lörincz, Balazs B

AU - Busch, Chia-Jung

AU - Knecht, Rainald

N1 - © 2015 Wiley Periodicals, Inc.

PY - 2016/4

Y1 - 2016/4

N2 - BACKGROUND: Significant evidence exists supporting the use of platinum-based chemoradiation (CRT) as a primary curative approach in locoregionally advanced head and neck cancer (LA-HNSCC). Despite these aggressive protocols, 70% of patients die within five years due to locoregional recurrence or distant metastasis. To increase the response and survival of HNSCC patients, CRT has been combined with molecular agents targeting distinct kinases.METHODS: This study was performed using a systematic literature review.RESULTS: The effect of targeted therapy on patient survival in the context of CRT remains controversial, with toxicities tending to be more severe but still acceptable.CONCLUSIONS: Supplementing CRT with target therapeutics might only improve survival in some LA-HNSCC patients. Therefore, future studies must address the underlying biological mechanisms which can have an impact on treatment response. Such knowledge is essential in order to facilitate the effective and personalized treatment of LA-HNSCC patients by combining CRT and targeted therapy. This article is protected by copyright. All rights reserved.

AB - BACKGROUND: Significant evidence exists supporting the use of platinum-based chemoradiation (CRT) as a primary curative approach in locoregionally advanced head and neck cancer (LA-HNSCC). Despite these aggressive protocols, 70% of patients die within five years due to locoregional recurrence or distant metastasis. To increase the response and survival of HNSCC patients, CRT has been combined with molecular agents targeting distinct kinases.METHODS: This study was performed using a systematic literature review.RESULTS: The effect of targeted therapy on patient survival in the context of CRT remains controversial, with toxicities tending to be more severe but still acceptable.CONCLUSIONS: Supplementing CRT with target therapeutics might only improve survival in some LA-HNSCC patients. Therefore, future studies must address the underlying biological mechanisms which can have an impact on treatment response. Such knowledge is essential in order to facilitate the effective and personalized treatment of LA-HNSCC patients by combining CRT and targeted therapy. This article is protected by copyright. All rights reserved.

U2 - 10.1002/hed.24031

DO - 10.1002/hed.24031

M3 - SCORING: Journal article

C2 - 25783524

VL - 38

SP - E2173-81

JO - HEAD NECK-J SCI SPEC

JF - HEAD NECK-J SCI SPEC

SN - 1043-3074

IS - Suppl 1

ER -